FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Lilly’s regulatory application seeking approval of Zepbound for OSA is also under review in the EU. Other than Zepbound, Lilly markets tirzepatide as Mounjaro for type II diabetes. Mounjaro and ...

FDA approves Zepbound for sleep apnea treatment, marking first such approval FDA grants landmark approval for obesity drug ...

Zepbound’s approval for OSA was based on data from SURMOUNT-OSA phase III studies. Lilly’s regulatory application seeking approval of Zepbound for OSA is also under review in the EU.

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.